Navigation Links
LSUHSC awarded patent for compound inhibiting cancer and other diseases
Date:10/6/2008

New Orleans, LA Dr. Eugene Woltering, the James D. Rives Professor of Surgery and Neurosciences at LSU Health Sciences Center New Orleans School of Medicine, and Dr. Conrad Hornick, former LSUHSC Professor of Physiology, have been awarded a US Patent for a compound to inhibit the formation of blood vessels critical to the growth of cancerous tumors and diseases like diabetic retinopathy, obesity, and psoriasis.

Apolipoprotein A-I is the major protein component of lipoproteins water soluble carrier molecules that transport cholesterol through the blood. LSUHSC researchers discovered that it can be used to destroy existing blood vessels as well as prevent the development of new vessels. For a tumor to grow bigger than 2 mm, the diameter of a large grain of sand, it must a have blood supply. Application of Apoliporpotein A-1 and high density lipoprotein has been proven effective in inhibiting tumor growth dependent upon angiogenesisthe process of developing new blood vessels. Studies have demonstrated that the level of vascularization in a tumor is strongly associated with metastasis in melanoma, breast, and lung carcinomas.

"This patent was based on the observation that lipid droplets are critical to the formation of the lumen of the blood vessels. By removing these fat droplets from the developing blood vessel we feel that we will be able to control the growth of new blood vessels that would feed tumors," notes Dr. Woltering.

There is also evidence that Apolipoprotein A-1 will be effective in treating other diseases reliant upon angiogenesis. In those diseases, angiogenesis is the root cause of tissue injury, including blindness associated with proliferative retinopathies, skin disorders such as psoriasis, and rheumatoid arthritis. Diseases that have been associated with abnormal blood vessel formation include Crohn's disease, diabetic retinopathy, macular degeneration, obesity, corneal neovascularization, benign tumors, hemangioma, arterial/venous malformations, sickle cell anemia, sarcoidosis, syphilis, pseudoxanthoma elasticum, Pagets disease, vein occlusion in the eye, infections of the retina, hyperparathyroidism, carotid obstructive disease, chronic uveitis/vitritis, mycobacterial infections, Lyme disease, systemic lupus erythematosis, psoriasis, myopia, optic pits, Stargarts disease, chronic retinal detachment, hyperviscosity syndrome, toxoplasmosis, trauma, rheumatoid arthritis, and post-laser complications.


'/>"/>

Contact: Leslie Capo
lcapo@lsuhsc.edu
504-452-9166
Louisiana State University Health Science Center
Source:Eurekalert

Related biology news :

1. LSUHSC awarded $10M+ COBRE grant
2. LSUHSCs Lazartigues awarded $1.2 million grant
3. LSUHSC research reports new method to protect brain cells from diseases like Alzheimers
4. 12 McGill researchers awarded Canada Research Chairs
5. Anthony S. Fauci awarded Lasker Award for Public Service
6. ETH Zurich professor Ari Helenius awarded Benoist Prize
7. Nanobiosym awarded $2 million DTRA contract
8. Mustafa alAbsi Ph.D. and national team awarded major NIH grant
9. Parus Interactive Awarded Patent for Speech-Activated Remote System Management
10. $2.7 million awarded for metastatic colon cancer research
11. UCR researchers awarded nearly $1.7M to develop improved cowpea varieties
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... , Feb. 24, 2017  EyeLock LLC, a leader of ... elite iris biometric solution on the latest Qualcomm® ... at Mobile World Congress 2017 (February 27 ... in Hall 3, Stand 3E10. ... Haven™ security platform—a combination of hardware, software ...
(Date:2/21/2017)... PORTLAND, Ore. , Feb. 22, 2017  IBM ... Companies (Avamere Health Services, Infinity Rehab, Signature Hospice, Home ... that will apply the power of IBM cognitive computing ... health centers. By analyzing data streaming from sensors in ... physical and environmental conditions, and obtain deeper learnings into ...
(Date:2/16/2017)... Feb. 16, 2017  Genos, a community for ... it has received Laboratory Accreditation from the College ... presented to laboratories that meet stringent requirements around ... rigorous processes. "Genos is committed to ... practices. We,re honored to be receiving CAP accreditation," ...
Breaking Biology News(10 mins):
(Date:2/23/2017)... ... February 23, 2017 , ... BellBrook Labs is ... include an array of biochemical analyses critical for Lead Discovery. The company’s ... and SAR programs, including inhibitor potency and selectivity, mechanism of action, and inhibitor ...
(Date:2/23/2017)... Feb. 23, 2017  MIODx announced today that ... key immunotherapy technologies from the University of California, ... method to monitor a patient for response to ... CTLA-4.  The second license extends the technology with ... likely to have an immune-related adverse event (IRAE) ...
(Date:2/23/2017)... 2017  Seattle,s upscale Capitol Hill neighborhood, with its swanky shops, ... a head lice treatment salon to set up shop. But ... and a French bistro on E Madison Ave, and CEO ... any old lice clinic, we pride ourselves on being a ... some of the stigma associated with lice. Everyone can get ...
(Date:2/23/2017)... ... February 23, 2017 , ... Brain Sentinel, Inc. has received ... SPEAC® System, the Brain Sentinel® Seizure Monitoring and Alerting System. The adjunctive seizure ... periods of rest. A lightweight, non-invasive monitor is placed on the belly of ...
Breaking Biology Technology: